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Abstract
Background: Cancer is frequently associated with tumor-related anemia, and many chemotherapeutic agents
impair hematopoiesis, leading to impaired quality of life for affected patients. The use of erythropoiesis-stimulating
agents has come under scrutiny after prospective clinical trials using recombinant erythropoietin to correct anemia
reported increased incidence of thromboembolic events and cancer-related deaths. Furthermore, previous preclinical
reports indicated expansion of the pool of breast cancer-initiating cells when erythropoietin was combined with
ionizing radiation.
Methods: Using four established breast cancer cell lines, we test the effects of recombinant human erythropoietin and
the number of breast cancer-initiating cells in vitro and in vivo and study if recombinant human erythropoietin promotes
the phenotype conversion of non-tumorigenic breast cancer cells into breast cancer-initiating cells. In a prospective study,
we evaluate whether elevated endogenous serum erythropoietin levels correlate with increased numbers of tumor-
initiating cells in a cohort of breast cancer patients who were scheduled to undergo radiation treatment.
Results: Our results indicate that recombinant erythropoietin increased the number of tumor-initiating cells in established
breast cancer lines in vitro. Irradiation of breast cancer xenografts caused a phenotype conversion of non-stem breast
cancer cells into induced breast cancer-initiating cells. This effect coincided with re-expression of the pluripotency factors
c-Myc, Sox2, and Oct4 and was enhanced by recombinant erythropoietin. Hemoglobin levels were inversely correlated
with serum erythropoietin levels, and the latter were correlated with disease stage. However, tumor sections revealed a
negative correlation between serum erythropoietin levels and the number of ALDH1A3-positive cells, a marker for breast
cancer-initiating cells.
Conclusions: We conclude that physiologically slow-rising serum erythropoietin levels in response to tumor-related or
chemotherapy-induced anemia, as opposed to large doses of recombinant erythropoietin, do not increase the pool of
breast cancer-initiating cells.
Keywords: Breast cancer-initiating cells, Erythropoietin, Radiation therapy
Background
Radiation therapy (RT) is an integral part of the
multi-modality treatment paradigm for breast cancer, as it
improves loco-regional control as well as breast cancer-re-
lated mortality [1]. The majority of patients experience dur-
able local control after radiotherapy for breast cancer.
However, for those few who do relapse locally, the impetus
is often unknown.
A large percentage of patients with breast cancer re-
quire chemotherapy as part of their treatment, which is
known to impair normal hematopoiesis, causing anemia.
Additionally, a substantial number of even early-stage
breast cancer patients suffer from tumor-related anemia
at the start of the treatment regimen [2] as cancers often
induce myelosuppressive cytokine profiles [3]. The
resulting low pre-treatment hemoglobin levels are corre-
lated with an unfavorable prognosis [2]. The underlying
mechanisms are incompletely understood, but low
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hemoglobin levels trigger the secretion of erythropoietin
[4], which has been shown to increase the number of ra-
diation and chemotherapy-resistant tumor-initiating cells
in breast cancer [5, 6] and glioma [7]. A substantial body
of evidence supports the view that erythropoietin is se-
creted within tumors in a para- and autocrine fashion
[7–9].
Recombinant human erythropoietin (rhEpo) has been
widely used in patients suffering from tumor-related or
chemotherapy-induced anemia to improve quality of life
(QOL) and to increase loco-regional tumor control after
RT [10]. Initially, rhEpo was FDA-approved for the treat-
ment of chemotherapy-induced anemia in cancer patients.
Studies designed to investigate the safety profile of rhEpo
in cancer patients did not indicate non-hematological
targets of Epo in vitro or in vivo.
While the vast majority of placebo-controlled prospective
clinical trials were designed to address the impact of rhEpo
on QOL, a few studies were designed with loco-regional
control or overall survival as primary endpoints. Unexpect-
edly, besides reporting an increased incidence of
cardio-vascular events, the latter studies revealed impaired
tumor control in patients treated with rhEpo [11–13]. Add-
itionally, a recent meta-analysis confirmed increased mor-
tality for cancer patients treated with rhEpo [10]. The use
of rhEpo in cancer patients is now restricted to palliative
settings.
Together these findings led us to hypothesize that ele-
vated endogenous erythropoietin levels could similarly in-
crease the aggressiveness of breast cancer and potentially
impair treatment outcomes. In the present study, we dem-
onstrate that in a cohort of breast cancer patients, while
endogenous erythropoietin levels were negatively corre-
lated with hemoglobin levels, higher erythropoietin levels
correlated with lower numbers of putative breast
cancer-initiating cells (BCICs) in the tumors.
Methods
Cell culture
Human SUM159PT breast cancer cell lines were purchased
from Asterand (Asterand, Inc., MI). Human MDA-
MB-231, MCF-7, and T47D breast cancer cell lines were
purchased from American Type Culture Collection (Ma-
nassas, VA). SUM159PT-ZsGreen-cODC, MDA-MB-231-
ZsGreen-cODC, MCF-7-ZsGreen-cODC, and T47D-ZsGr
een-cODC cell lines were obtained as described previously
[14]. SUM159PT cells were cultured in log-growth phase in
F12 Medium (Invitrogen, Carlsbad, CA) supplemented with
5% fetal bovine serum (FBS; Sigma Aldrich, St Louis, MO),
penicillin (100 units/ml) and streptomycin (100 μg/ml)
(both Invitrogen), and insulin (5 μg/mL) and hydrocorti-
sone (1 μg/ml). MCF-7 cells were cultured in MEM media
supplemented with non-essential amino acids, sodium
pyruvate, insulin, penicillin, streptomycin, and 10% FBS.
MDA-MB-231 and T47D cells were cultured in log-growth
phase in Dulbecco’s modified Eagle’s medium (DMEM)
(Invitrogen) supplemented with 10% fetal bovine serum,
penicillin, and streptomycin. All cells were grown in a hu-
midified incubator at 37 °C with 5% CO2. Cell line identities
were confirmed by DNA fingerprinting (Laragen, Culver
City, CA).
Animals
Six- to 8-week-old NOD-scid IL2Rgammanull (NSG) mice,
originally obtained from The Jackson Laboratories (Bar
Harbor, ME), were re-derived, bred, and maintained in a
pathogen-free environment in the American Association
of Laboratory Animal Care-accredited Animal Facilities of
the Department of Radiation Oncology, University of Cali-
fornia (Los Angeles, CA), in accordance to all local and
national guidelines for the care of animals. Weight of the
animals was recorded every 2 days.
Flow cytometry
Mammospheres were harvested, dissociated using Try-
pLE (Thermo Fisher Scientific) and fire-polished Pasteur
pipettes, and passed through a 70-μm sieve (Millipore).
Explanted tumors were digested using a GentleMACS
dissociator (Miltenyi Biosciences, Auburn, CA). Single-
cell suspensions were subjected to flow cytometry (MAC
SQuant Analyzer, Miltenyi), and ZsGreen and/or BFP
expression was analyzed using the FlowJo software pack-
age (v10, FlowJo, Ashland, OR).
BCICs and non-stem breast cancer cells were isolated
based on the expression of our reporter construct using
high-speed FACS.
In vitro sphere formation assay
In order to assess self-renewal capacity, cells were trypsi-
nized and plated in mammosphere media (DMEM-F12,
0.4% BSA (Sigma), 10 ml/500 ml B27 (Invitrogen) 5 μg/
ml bovine insulin (Sigma), 4 μg/ml heparin (Sigma), 20
ng/ml fibroblast growth factor 2 (bFGF, Sigma), and 20
ng/ml epidermal growth factor (EGF, Sigma)) into
96-well ultra-low adhesion plates, ranging from 1 to 256
cells/well. Growth factors, EGF and bFGF, were added
every 3 days, and the cells were allowed to form mam-
mospheres for 20 days. The number of spheres formed
per well was then counted and expressed as a percentage
of the initial number of cells plated.
Quantitative reverse transcription-PCR
Total RNA was isolated using TRIZOL Reagent (Invitro-
gen). cDNA synthesis was carried out using the Super-
Script Reverse Transcription III (Invitrogen). Quant
itative PCR was performed in the My iQ thermal cycler
(Bio-Rad, Hercules, CA) using the 2× iQ SYBR Green
Supermix (Bio-Rad). Ct for each gene was determined
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after normalization to PPIA, TBP, and IPO8, and ΔΔCt
was calculated relative to the designated reference sam-
ple. Gene expression values were then set equal to
2−ΔΔCt as described by the manufacturer of the kit (Ap-
plied Biosystems). All PCR primers were synthesized by
Invitrogen and designed for the human sequences of
Oct4, Sox2, Nanog, Klf4, c-Myc, and the housekeeping
genes PPIA, TBP, and IPO8. Primer sequences are listed
in an additional file (see Additional file 1).
In vivo limiting dilution assay
High-speed FACS based on the accumulation of the
ZsGreen reporter protein was used to sort SUM159PT-
ZsGreen-cODC breast cancer cells. 102–106 ZsGreen-
positive or ZsGreen-negative cells were injected s.c. into
the flanks of 6–8-week-old NSG mice. Tumor formation
was monitored for 16 weeks after injection. Frequencies of
tumor-initiating cells were calculated as described in [15].
Irradiation
Cells were irradiated at room temperature using an ex-
perimental X-ray irradiator (Gulmay Medical Inc. At-
lanta, GA) at a dose rate of 5.519 Gy/min for the time
required to apply a prescribed dose. The X-ray beam
was operated at 300 kV and hardened using a 4-mm Be,
a 3-mm Al, and a 1.5-mm Cu filter. Corresponding con-
trols were sham irradiated.
For tumor irradiation studies, the animals were anes-
thetized with isofluorane. Tumors growing subcutane-
ously were localized in cone beam CT images,
contoured in the SmART Plan software package and ir-
radiated using a single beam from an image-guided
small animal irradiator with a 10-mm circular collima-
tor. The X-ray beam was operated at 225 KV (SmART,
Precision X-Ray).
NIST-traceable dosimetry was performed on both
X-ray machines.
In vivo drug treatment
In order to test the effect of erythropoietin on
radiation-induced reprogramming in vivo SUM159PT cells
were stably infected with lenti-viral vectors coding for
ZsGreen-cODC or BFP/ZsGreen-cODC. ZsGreen-cODC-
positive intrinsic tumor-initiating cells were co-injected
with BFP-positive/ZsGreen-cODC-negative, non-tumorige-
nic cells. When tumors reached 0.5 cm in diameter, a single
radiation dose of 4Gy was applied to the tumor. From the
day of radiation treatment erythropoietin was administered
for five consecutive days at 500 IU/kg i.p. (AMGEN, Thou-
sand Oaks, CA), starting 3 h before irradiation of the tu-
mors. Control animals received a single radiation dose of 4
Gy to the tumor and/or saline injections. Twenty-four
hours after the final application of erythropoietin mice were
euthanized and the tumors explanted. Explanted tumors
were analyzed for the induction of BCICs and stained for
Klf4 expression using an anti-Klf4 antibody (Abcam,
ab215036, 1:2000 dilution), and Sox2 expression using an
anti-Sox2 antibody (Cell Signaling Technology, 14962S,
1:50 dilution) overnight at 4 °C. The slides were digitized
on a ScanScope AT (Aperio Technologies, Inc., Vista, CA)
and morphimetric analysis performed with Definiens’ Tis-
sue Studio (Definiens Inc., Parsippany, NJ) to determine the
percentage of Klf4- and Sox2-positive cells in a non-biased
method. Briefly, using the pre-defined nuclear detection
module and classification tool, positive and negative nuclei
within each tissue cross section were identified. Thresholds
were set to classify hematoxylin stain for negative nuclei
and 3,3′-diaminobenzidine (DAB) stain for positive nuclei.
The data were exported to GraphPad Prism for further stat-
istical analysis.
Scanning and analysis were performed through the
Translational Pathology Core Laboratory, Department of
Pathology and Laboratory Medicine, David Geffen School
of Medicine at UCLA.
Patients
Female breast cancer patients treated between December
2012 and July 2016 at the Department of Radiation Oncol-
ogy at the University of California, Los Angeles, were in-
cluded in this study. The study was approved by the local
ethics committee and performed in accordance with the
revised Declaration of Helsinki. Serum samples were ob-
tained before the start of radiation treatment. None of the
patients received erythropoietin medication before the
blood sampling and start of radiation treatment. Complete
follow-up data were available through May 2017. As of
May 2017, 96/99 patients were disease-free and alive.
Erythropoietin enzyme-linked immunosorbent assays
Enzyme-linked immunosorbent assays (ELISA) were
performed by following the manufacturer’s instructions
(Human Erythropoietin Quantikine IVD ELISA Kit, R&D
Systems, Minneapolis, MN). Briefly, 100 μL of erythropoi-
etin (Epo) assay diluent was added to each well of the hu-
man erythropoietin-specific ELISA strip. One hundred
microliters of standard, control, or serum samples from
patients was added to each well and incubated for 2 h at
room temperature (RT). The unknown serum samples
were run in duplicates. The wells were thoroughly aspi-
rated, and 200 μL of erythropoietin conjugate was added
to each well and incubated for 2 h at RT. After washing
for four times, 200 μL of substrate solution was added to
each well. Plates were incubated at RT for 20–25min after
which the reaction was quenched by adding 100 μL of stop
solution. The absorbance was read at 450 nm (Spectramax
M5, Molecular Devices, Sunnyvale, CA). A wavelength
correction was performed by subtracting readings at 600
nm from the readings at 450 nm. A standard curve was
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generated (GraphPad Prism, version 6), and the concen-
trations of erythropoietin in each serum sample were cal-
culated by plotting the unknown O.D. values against the
standard.
Tissue microarrays
Tissue microarrays were constructed by the UCLA Trans-
lational Pathology Core Laboratory using a Veridiam
VTA-110CC Semiautomated Tissue Arrayer using stand-
ard protocols. Tissue microarrays were stained against
ALDH1A3 using a rabbit anti-human ALDH1A3 antibody
(Thermo Fisher Scientific, PA5-29188) at the dilution of
1:1000 overnight at 4 °C, and against PSMD1 antibody
(Abcam, ab2941) at the dilution of 1:500 overnight at 4 °
C. The slides were rinsed with PBST and were incubated
with Dako EnVision+ System- HRP Labeled Polymer
Anti-Rabbit (Dako, K4003) at room temperature for 30
min. After a rinse with PBST, the slides were incubated
with DAB (3,3′-diaminobenzidine) for visualization. Sub-
sequently, the slides were washed in tap water, counter-
stained with Harris’ Hematoxylin, dehydrated in ethanol,
and mounted with media. Tumor cores were scored by a
board-certified breast cancer pathologist based on
ALDH1A3 expression on membranes and cytoplasm or
cytoplasmic PSMD1 expression on a scale from 0 to + 3
(0: no reaction, + 1 reaction barely visible, + 2 reaction
clearly visible, + 3 reaction intense). ALDH1A1 expression
was scored by the same principle.
Statistical methods
Unless indicated otherwise, all data result from at least
three biologically independent experiments. A p value of
0.05 in Student’s t test or ANOVA (SAS JMP, version 13)
was considered an indicator for statistical significance.
For analyzing the clinical data, descriptive statistics
such as mean and standard deviation were used to
summarize continuous variables, while count and per-
centage were used for categorical variables. Student’s t
test or univariate logistic regression was performed to
evaluate the association between serum Epo levels vs
PSMD1 expression and Epo vs ALDH1A3 expression. A
multivariable linear regression model for Epo was con-
structed by including PSMD1 (yes (score 2 or 3) vs no
(score 0 or 1)), and ALDH1A3 (yes (score 2 or 3) vs no
(score 0 or 1)), age, cancer stage, Hb, triple-negative (yes
vs no), chemo (yes vs no), receptor (positive vs negative),
and histology. Model diagnostics were performed to as-
sess the final multivariate regression model. For all stat-
istical investigations, tests for significance were two-
tailed, with a statistically significant p value threshold of
0.05. Statistical analyses were carried out using SAS ver-
sion 9.2 (SAS Institute Inc., Cary, NC).
Results
Breast cancer cells with low 26S proteasome activity have
increased tumorigenicity
We had previously demonstrated that BCICs downregulate
proteasome subunit expression and function via binding of
Musashi1 to the mRNA of NF-YA [16], a component of
NF-Y, the master regulator of proteasome subunit expres-
sion [17]. Furthermore, we developed an imaging system
that allows for tracking and targeting of BCICs based on
the accumulation of a fusion protein of the fluorescent pro-
tein ZsGreen and the C-terminal degron of murine orni-
thine decarboxylase. In cells with low proteasome activity,
the fusion protein cannot be degraded and allows for iden-
tifying these cells by flow cytometry [14, 18]. Importantly,
breast cancer cells with low proteasome activity overlap
with cells that exhibit high ALDH1 activity [19]. To dem-
onstrate that SUM159PT breast cancer cells with low pro-
teasome activity are enriched for BCICs, we performed an
in vivo limiting dilution assay. 102–106 cells with high
(ZsGreen-negative) or low (ZsGreen-positive) proteasome
activity were injected into the flanks of female NSG mice.
Tumor-initiating cell frequency was found to be 1:2586 in
ZsGreen-positive cells and 1:72,886 in ZsGreen-negative
cells (Table 1, p < 0.0001). This level of BCIC enrichment
compared well to other used markers in the field [20], thus
supporting the validity of our reporter system as a marker
for BCICs in this triple-negative breast cancer line.
Radiation-induced enrichment of tumor-initiating cells
and erythropoietin
In our previous studies, we found that radiation selects
for radiation-resistant tumor-initiating cells in breast
cancer [21, 22] and others have confirmed our findings
[23]. Furthermore, we reported that erythropoietin in-
creased the number of CD24−/low/CD44high cells in vitro
and increased mammosphere formation [5]. This marker
combination was the first profile identified to enrich for
BCICs [24]. When we treated mammospheres of
MCF-7, T47D, MDA-MB-231, or SUM159PT cells with
erythropoietin (1 IU/ml) and/or 0, 2, 4, 6, and 8 Gy or
5 × 3 Gy of radiation, we observed a significant radiation
dose-dependent increase in the number of
ZsGreen-positive BCICs (Fig. 1a–d), which was in agree-
ment with our previous reports [21, 22]. However,
addition of erythropoietin enhanced this effect only in
Sum159PT cells and only after 8 Gy (Fig. 1d).
Radiation-induced phenotype conversion of non-
tumorigenic cells and erythropoietin
Increased numbers of BCICs observed after radiation treat-
ment are not solely a result of their intrinsic relative radio-
resistance [21, 22] and selective killing of non-tumorigenic
cells but also caused by radiation-induced phenotype con-
version of non-tumorigenic breast cancer cells into BCICs
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Table 1 In vivo limiting dilution assay with SUM159-ZsGreen-cODC cells
Fig. 1 rhEpo enriches for the intrinsic BCICs in vitro. a MCF7-ZsGreen-cODC, b T47D-ZsGreen-cODC, and c MDA-MB-231-ZsGreen-cODC were
plated into sphere cultures. d SUM150PT-ZsGreen-cODC were plated in adherent conditions. a–d The cells were treated with 1 IU/ml rhEpo (gray
bars) or vehicle (black bars) and 1 h later were subjected to 0, 4, and 8 Gy or five daily doses of 3 Gy. Six days after Epo treatment, the cells were
harvested and analyzed by flow cytometry. The graph represents the average %ZsGreen-positive BCICs from at least three independent repeats ±
SEM. * p < 0.05, ** p < 0.01
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[19]. This radiation-induced phenotype conversion can be
reduced by inhibiting the PI3K and Notch pathways [5, 19].
Because erythropoietin is known to activate both the PI3K
[25] and Notch signaling pathways [5], we sought to test if
erythropoietin also promotes radiation-induced phenotype
conversion.
In order to remove intrinsic BCICs, ZsGreen-cODC-
expressing breast cancer cells were depleted from
ZsGreen-positive BCICs using FACS. The remaining
ZsGreen-negative non-stem breast cancer cells were ir-
radiated with 0, 2, 4, 6, and 8 Gy or 5 × 3 Gy and treated
with 0 or 1 IU/ml of rhEpo. Five days after radiation
treatment, the number of induced BCICs was assessed
by flow cytometry. Single radiation doses led to a dose-
dependent increase in the number of induced BCICs,
and this effect was most pronounced in triple-negative
MDA-MB-231 and SUM159PT cells. Five daily doses of
3 Gy also induced the formation of BCICs, and both
findings were in agreement with our previously pub-
lished data [19]. The addition of rhEpo enhanced this ef-
fect (Fig. 2).
To further explore if this phenomenon occurs also in
vivo, we sorted ZsGreen-cODC-negative cells from cells
and injected them into NSG mice. Flank tumors were ir-
radiated with a single dose of 0 or 4 Gy (Fig. 3a). Ani-
mals were injected with rhEpo once daily for 5 days.
When the tumors were explanted on day 6 after irradi-
ation and cells were analyzed by flow cytometry, we
found a 1.2-fold increase in the number of induced
BCICs in tumors treated with 4 Gy. Treatment of the
animals with rhEpo led to a significant 2.3-fold increase
in the number of BCICs (Fig. 3b; p = 0.02, unpaired,
two-sided Student’s t test).
Erythropoietin induces Yamanaka factor expression in
breast cancer cells
We previously reported that radiation led to re-express-
ion of Yamanaka factors in non-BCICs. To test if rhEPo
would augment this effect, SUM159PT-ZsGreen-nega-
tive cells were obtained by FACS, irradiated with 4 Gy
and treated for four consecutive days with 1 IU/ml
rhEpo. Five days after irradiation, induced breast cancer
Fig. 2 rhEpo enhances radiation-induced phenotype conversion in vitro. a MCF7-ZsGreen-cODC, b T47D-ZsGreen-cODC, c MDA-MB-231-ZsGreen-
cODC, and d SUM150PT-ZsGreen-cODC were depleted of intrinsic BCICs by sorting for ZsGreen-negative cells. The cells were plated and the
following day were treated with vehicle (light gray), 1 IU/ml rhEpo (dark gray), or 10 IU/ml rhEpo (black). One hour later, the cells were subjected
to 0, 4, and 8 Gy or five daily doses of 3 Gy. Six days after rhEpo treatment, the cells were harvested and analyzed by flow cytometry. Graph
represents the average %ZsGreen-positive cells from at least four independent repeats ± SEM. Statistical significance was determined by Student’s
t tests. * p < 0.05, ** p < 0.01
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initiating cells (iBCICs) were re-sorted by FACS and
Yamanaka factor expression was analyzed by qRT-PCR.
A single dose of 8 Gy significantly increased c-Myc,
Oct4, Sox2, and Nanog mRNA expression in
non-irradiated cells while treatment with rhEpo alone
significantly increased c-Myc expression (Fig. 4a). Com-
bined treatment with rhEpo and radiation enhanced the
effect of radiation leading to a significant increase in
c-Myc, Sox2, Klf4, and Nanog expression (Fig. 4a).
Next, we tested if combining irradiation with rhEpo
would increase Yamanaka factor protein expression in
vivo. Mice, bearing SUM159PT xenografts, were
treated with radiation using an image-guided small
animal irradiator and rhEpo. Five days after irradi-
ation, tumors were explanted and tumor sections
stained for Sox2 and Klf4 and subjected to an auto-
mated image analysis. The combined treatment with
radiation and rhEpo significantly increased the
Fig. 3 rhEpo enhances radiation-induced phenotype conversion in vivo. SUM159PT-StrawberryRed-ZsGreen-cODC cells were sorted for
StrawberryRed-positive and ZsGreen-negative cells, and the sorted cells were mixed with Matrigel and implanted into the flank of female 6-week-old
NSG mice at a density of 106 cells per site. Injection sites were monitored weekly for tumor formation. When the tumors reached ~ 3–5mm, the
mouse was treated intraperitoneally with 500 IU/kg rhEpo or vehicle. Three hours after rhEpo treatment, the mice were anesthetized, and cone beam
CT images were obtained using an image-guided small animal irradiator. a An individualized treatment plan was generated for each tumor to apply a
4 Gy dose to the tumor using a single beam. The smaller green circle represents the target, and the pale green regions represent the regions covered
by the applied beam. b The mice were administered daily injections of rhEpo or vehicle for a total of 5 days. After the final treatment, the tumors were
harvested and digested into single cells. The cell suspensions were analyzed by flow cytometry for the induced BCIC population (StrawberryRed-
positive, ZsGreen-positive). The graph represents the normalized %ZsGreen-positive tumor cells observed in at least four animals per group ± SEM
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number of Klf4-positive tumor cells (Fig. 4b;
2.16-fold, p = 0.019, unpaired, two-sided Student’s t
test). The number of Sox2-positive cells after com-
bined treatment increased 5.3-fold but did not reach
significance levels (Fig. 4b).
High serum erythropoietin levels correlate with low
numbers of ALDH1A3-expressing breast cancer cells
Finally, we sought to study if elevated endogenous erythro-
poietin would increase the number of tumor-initiating cells
in breast cancer patients. Ninety-nine patients with
Fig. 4 rhEpo induces Yamanaka factor expression in breast cancer cells in vitro and in vivo. SUM159PT-ZsGreen-cODC cells were depleted of intrinsic stem
cells by sorting for the ZsGreen-negative population. a These cells were plated and, the following day, were treated with 1 IU/ml rhEpo or vehicle followed
1 h later by irradiation with 0 or 8 Gy. Five days later, the cells were sorted for ZsGreen-negative and ZsGreen-positive cells. Expression of the Yamanaka
factors were measured by qRT-PCR and normalized to GAPDH and the ZsGreen-negative population from the control sample. Bars represent the average
fold increase in mRNA expression obtained from three independent repeats ± SEM. Statistical significance was determined by multiple t tests with a false
discovery rate of 1%. * p< 0.05, ** p< 0.01. b BCIC-depleted SUM159PT-ZsGreen-cODC cells were implanted subcutaneously into the flanks of female 6–8-
week-old NSG mice. Injection sites were monitored weekly for tumor formation. When the tumors reached ~ 3–5mm, the mouse was treated
intraperitonally with 500 IU/kg rhEpo or vehicle. Three hours after rhEpo treatment, the mice were treated with a 4-Gy dose to the tumor using a single
beam. The mice were administered daily injections of rhEpo or vehicle (i.p.) for a total of 5 days. After the final treatment, the tumors were harvested, fixed,
embedded, and sectioned. The sections were stained for Klf4 and Sox2, representative images shown. The % stained cells were quantified using a non-
biased automated nuclei counting software. The graphs represent the % Klf4- or Sox2-stained cells normalized to the 0 Gy, vehicle-treated group from four
individual animals per group ± SEM. Statistical significance was determined by Student’s t tests. * p< 0.05
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primary, non-metastatic breast cancer were included in the
study. Patient characteristics are summarized in Table 2.
Pre-radiotherapy hemoglobin levels were available for 92
patients. The median hemoglobin concentration was 12.8
g/dl. Serum erythropoietin levels correlated with the disease
stage (p = 0.049, ANOVA) were elevated (> 19.5mU/ml) in
29 patients and were inversely correlated with the
hemoglobin concentration (p < 0.0001). Tumor cores were
available for 52 patients. When age, disease stage, receptor
status, the presence of a triple-negative tumor, hemoglobin
concentration, neoadjuvant chemotherapy, and erythropoi-
etin serum levels were fitted using a logistic regression
model, high serum erythropoietin levels correlated with de-
creased numbers of cells expressing the A3 isoform of alde-
hyde dehydrogenase 1 (ALDH1A3) (Fig. 5; p = 0.0153,
Table 3), a marker for BCICs [26–29]. Staining against the
proteasome subunit PSMD1, a marker correlated with
worsened outcome in glioblastoma [30] and cancer of the
head and neck [31], was not informative because all tumor
cores showed high or very high expression levels for
PSMD1, thus supporting the rare nature of BCICs. Like-
wise, staining of the tumor sections with and antibody
against the A1 isoform of ALDH1 did not show any correl-
ation with serum erythropoietin levels (data not shown).
Discussion
In general, the structural organization of tumors can be
described using two competing models: (1) a stochastic
model in which every cell in a tumor has the potential
of unlimited self-renewal and multi-lineage potency and
(2) a hierarchical model in which this phenotype is re-
stricted to a small number of cancer-initiating cells
(CICs) [32]. There is now ample evidence favoring the
hierarchical model over the stochastic model in many
solid cancers [33–42] including breast cancer [24]. Based
on cell surface markers or enzymatic activity of ALDH1,
several studies prospectively identified cell populations
highly enriched for BCICs [26–29]. Importantly, in clin-
ical breast cancer samples, the expression of the A3 iso-
form of ALDH1 is predicative of tumor grade,
metastasis, and cancer stage [43].
In the present study, we explored if erythropoietin in-
creases the plasticity of breast cancer cells and tested
the hypothesis that elevated endogenous serum erythro-
poietin levels in breast cancer patients increase the ag-
gressiveness of breast cancer through expansion of the
pool of BCICs, analogous to the effects seen after
Table 2 Baseline demographic and tumor-related characteristics
Age Median (range) 60 (29–86)
Race No, %
African American 6 (6)
Asian 13 (13)
Indian 2 (2)
White 63 (64)
Other/unknown 5 (5)
BMI kg/m2, mean (SD)
27.5 (6.0)
Height cm, mean (SD)
162.5 (7.6)
Weight kg, mean (SD)
72.9 (19.9)
ECOG PS No (%)
0 85 (86)
1 6 (6)
2 5 (5)
Unknown 3 (3)
Postmenopausal status No (%)
Yes 69 (70)
Stage Stage No (%)
0 19 (19)
I 28 (27)
II 41 (41)
III 11 (11)
Neoadj ChT Yes 20 (20)
Surgery Type No
Breast conserving 77
Mastectomy 11
Bilat. mastectomy 11
Receptor status No (%)
ER Positive 77 (78)
Negative 22 (22)
PR Positive 66 (67)
Negative 33 (33)
Her2 Positive 14 (14)
Negative 70 (71)
Unknown 15 (15)
Hemoglobin, g/dl
Mean (SD) 12.3 (1.7)
Median (range) 12.8 (8.9–15)
Category No (%)
< 9 2 (2.2)
9 to < 10 9 (9.8)
≥ 10 81 (88)
Table 2 Baseline demographic and tumor-related characteristics
(Continued)
Erythropoietin, IU/l
Mean (SD) 19.2 (9.6)
Median (range) 16.8 (8.5–60.9)
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treatment of breast cancer cell lines with rhEpo and the
unfavorable results from randomized trials using rhEpo
in anemic cancer patients [12, 44, 45].
Preclinical studies to date have failed to conclusively
describe the effects of rhEpo on tumors, with some stud-
ies observing no effect on cancer cells [46], others report
anti-cancer activity of rhEpo [47–49], and still others de-
scribe tumor-promoting effects of rhEpo [50–55]. We,
and others, have reported that radiation induces less
ROS formation and DNA DSBs in CICs [21, 30, 56] and
that cell cycle checkpoints are activated more efficiently
in CICs [57]. This results in a relatively radioresistant
phenotype of CSCs [21, 23, 57] and a relative and abso-
lute increase in the number of CICs after fractionated ir-
radiation [22]. However, factoring in the long doubling
time of BCICs, which remained unchanged after irradi-
ation, and their intrinsic radiosensitivity, we consistently
found absolute numbers of BCICs that could not be
Fig. 5 Sample cores of breast cancer specimen stained for ALDH1A3. Sample cores are shown at 10× (upper row) and 25× (lower row). Cores
were scored based on the highest staining observed: Core one (left) with 40% of the cells staining “+ 1” and 60% staining “0” was scored “+ 1.”
Core two (right) with 80% of the cells staining “+ 1” and 20% staining “+ 2” was scored “+ 2”. Scale bars = 100 μm
Table 3 Analysis of maximum likelihood estimates
Parameter DF Estimate Standard error Wald chi-square Pr > ChiSq
Intercept 1 15.1728 25.4962 0.3541 0.5518
Epo (mIU/mL) 1 − 0.1674 0.0664 6.3653 0.0116
Age 1 − 0.0352 0.0331 1.1282 0.2881
Numeric stage 0 1 − 20.4155 224.3 0.0083 0.9275
Numeric stage 1 1 5.6702 74.7554 0.0058 0.9395
Numeric stage 2 1 5.8172 74.7587 0.0061 0.9380
Hgb 1 − 0.5733 0.3153 3.3058 0.0690
Triple negative 0 1 5.2131 33.6736 0.0240 0.8770
Chemotherapy 0 1 1.0505 0.7933 1.7536 0.1854
Receptor status 0 1 5.6305 33.6720 0.0280 0.8672
Histology DCIS 1 19.3640 199.3 0.0094 0.9226
Histology IDC 1 − 9.4229 99.6720 0.0089 0.9247
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easily explained by symmetric division of existing CICs
[22]. In a follow-up study, we reported that radiation in-
duced a phenotype conversion of non-tumorigenic
breast cancer cells into BCICs [19], thus offering an add-
itional explanation for the observed increase of BCICs
after irradiation. In the present study, we confirmed that
radiation enriches for putative BCICs in established
breast cancer cell lines. Treatment of the cells with
rhEpo showed a trend to enhance this phenomenon in
vitro. Likewise, removal of BCICs before irradiation con-
firmed the radiation dose-dependent generation of in-
duced BCICs from non-stem breast cancer cells, an
effect that was enhanced by treatment with rhEpo. How-
ever, in both experiments, the increase in the number of
CICs that could be attributed to rhEpo treatment was
rather small. This was in agreement with a previous
study finding rhEpo to more efficiently promote breast
cancer in vivo than in vitro [58].
We report here for the first time that radiation-induced
phenotype conversion can be observed when breast cancer
xenografts are irradiated in vivo. This effect was significantly
increased when radiation and rhEpo were combined. Given
the small effects of rhEpo on radiation-induced phenotype
conversion in vitro, it suggests that the effects of rhEpo that
lead to increased phenotype conversion in irradiated tumors
are at least co-mediated by a stromal component.
As expected, we found an inverse correlation between
hemoglobin and serum erythropoietin levels in a cohort of
breast cancer patients scheduled to undergo radiation
treatment and mean serum erythropoietin levels corre-
lated with disease stage. Henke et al. previously reported a
correlation between low serum hemoglobin levels and
disease-free survival in early-stage breast cancer patients
receiving breast-conserving surgery followed by adjuvant
radiotherapy [2].
The data presented in the present study indicate that
more advanced breast cancers more efficiently suppress
erythropoiesis even in the presence of elevated serum
erythropoietin levels. However, when we stained for
ALDH1A3, a known marker for breast CICs [43], we
found serum erythropoietin levels negatively correlated
with the number of putative breast CICs in the tumor
sections. This was unexpected and, in the light of our
experimental data, suggests different effects of slowly
rising endogenous erythropoietin levels in response to
tumor-related anemia as opposed to relatively large and
rapid increases through application of rhEpo in vitro or
in vivo. Another explanation could be a differential effect
of endogenous and recombinant human erythropoietin
on cancer cells. Endogenous and recombinant erythro-
poietin differ substantially in their levels of glycosylation
and protein structure with consequences for receptor
binding affinity and protein stability, differences which
are utilized to detect blood doping in athletes [59].
Conclusions
While all forms of erythropoietin undisputedly stimulate
erythropoiesis through the erythropoietin receptor, the
consequences of the structural differences for potential
off-target effects are currently not well understood and
could explain the observed discrepancy between our in
vitro and in vivo studies on the one hand and our clinical
observations on the other. Further studies are warranted
to better understand functional differences of the multiple
forms of erythropoietin on tumor cells.
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